1. Home
  2. RVPH vs GDO Comparison

RVPH vs GDO Comparison

Compare RVPH & GDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • GDO
  • Stock Information
  • Founded
  • RVPH 2006
  • GDO 2009
  • Country
  • RVPH United States
  • GDO United States
  • Employees
  • RVPH N/A
  • GDO N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • GDO Finance Companies
  • Sector
  • RVPH Health Care
  • GDO Finance
  • Exchange
  • RVPH Nasdaq
  • GDO Nasdaq
  • Market Cap
  • RVPH 88.0M
  • GDO 84.5M
  • IPO Year
  • RVPH N/A
  • GDO N/A
  • Fundamental
  • Price
  • RVPH $1.87
  • GDO $11.36
  • Analyst Decision
  • RVPH Strong Buy
  • GDO
  • Analyst Count
  • RVPH 5
  • GDO 0
  • Target Price
  • RVPH $11.40
  • GDO N/A
  • AVG Volume (30 Days)
  • RVPH 1.5M
  • GDO 39.4K
  • Earning Date
  • RVPH 11-14-2024
  • GDO 01-01-0001
  • Dividend Yield
  • RVPH N/A
  • GDO 9.81%
  • EPS Growth
  • RVPH N/A
  • GDO N/A
  • EPS
  • RVPH N/A
  • GDO N/A
  • Revenue
  • RVPH N/A
  • GDO N/A
  • Revenue This Year
  • RVPH N/A
  • GDO N/A
  • Revenue Next Year
  • RVPH N/A
  • GDO N/A
  • P/E Ratio
  • RVPH N/A
  • GDO N/A
  • Revenue Growth
  • RVPH N/A
  • GDO N/A
  • 52 Week Low
  • RVPH $0.60
  • GDO $11.21
  • 52 Week High
  • RVPH $4.72
  • GDO $13.04
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 48.62
  • GDO 53.45
  • Support Level
  • RVPH $1.97
  • GDO $11.34
  • Resistance Level
  • RVPH $2.14
  • GDO $11.49
  • Average True Range (ATR)
  • RVPH 0.16
  • GDO 0.08
  • MACD
  • RVPH -0.01
  • GDO 0.02
  • Stochastic Oscillator
  • RVPH 40.43
  • GDO 55.17

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.

Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.

Share on Social Networks: